CTLA4 and cancer: Importantly, higher PD-L1 and CTLA4 expression levels were observed in the PTPRD/PTPRT mutant cancer patients, compared with WT patients, suggesting that ICI treatment is more applicable for PTPRD/PTPRT mutant cancer patients.